AirSculpt Technologies announced the formal introduction of its latest procedure, AirSculpt Lift. In the wake of the FDA’s recent warning about the potential side effects of synthetic dermal filler, AirSculpt Lift offers a safe, natural and lasting alternative for anyone who uses synthetic fillers to eliminate wrinkles or restore volume to their face.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AIRS:
- AirSculpt® Technologies, Inc. Introduces AirSculpt Lift, an Alternative to Synthetic Dermal Fillers
- AirSculpt Technologies backs FY23 revenue view $187M-$192M, consensus $191.47M
- AirSculpt Technologies Announces Second Quarter 2023 Results and Reaffirms 2023 Guidance
- AirSculpt Technologies reports Q2 adjusted EPS 13c, consensus 5c
- AIRS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
